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httpcense.Abstract Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inﬂammatory
mediator used as a novel marker for vascular speciﬁc inﬂammation, atherosclerosis and cardiovas-
cular risks in humans. Both chronic obstructive pulmonary disease (COPD) and obstructive sleep
apnea (OSA) are associated with frequent cortical arousals on polysomnography, and increased
activation of inﬂammatory cells and molecular mechanisms associated with atherosclerosis and
cardiovascular complications.
Objective: To study the relation between Lp-PLA2 level as a marker of cardiovascular risks and
arousal index in patients with OSA, COPD and overlap syndrome (COPD+ OSA).
Patients and methods: Sixty participants were recruited, divided into four groups (15 in each
group) based on their polysomnographic and spirometric data; group I (normal), group II
(OSA), group III (COPD) and group IV (overlap syndrome). Fasting serum samples were used
to estimate lipid proﬁle and Lp-PLA2 concentrations.e lung disease; OSA, obstruc-
associated phospholipase A2;
ypopnea index; FEV1, forced
C, forced vital capacity; ESS,
ensity lipoprotein; LDL, low
inked immunosorbant assay;
turation index
8818827.
m (M. Yousif).
e Egyptian Society of Chest
g by Elsevier
ng by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and Tuberculosis.
://dx.doi.org/10.1016/j.ejcdt.2014.01.012
406 E.A.E. Badr et al.Results: The apnea–hypopnea, arousal, desaturation indices, lipid proﬁle and Lp-PLA2 levels
were signiﬁcantly increased in all patient groups compared to control. The arousal index and Lp-
PLA2 level were signiﬁcantly increased in overlap syndrome more than OSA and COPD patients.
Lp-PLA2 level was independent predictor of arousal index in all patient groups.
Conclusions: Patients with overlap syndrome have a higher arousal index andLp-PLA2 level hence
more cardiovascular risks than either OSA or COPD alone. The Lp-PLA2 level may be used as an
independent predictor of cardiovascular risks in patients with OSA, COPD and overlap syndrome.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
COPD and OSA represent two of the most prevalent chronic
respiratory disorders in clinical practice, and the term ‘‘overlap
syndrome’’ is commonly used to describe the association
between them, when coexisting. It occurs in about 10–20%
of patients with OSA [1]. The possible coexistence of COPD
with OSA is important because systemic inﬂammation devel-
ops in each disorder [2]. Both COPD and OSA are associated
with increased activation of many inﬂammatory cells and
molecular changes associated with atherosclerosis [3,4]. This
provides basic mechanisms to support the clinical and epidemi-
ological data demonstrating them as independent risk factors
for cardiovascular diseases [3,5,6]. Moreover, sleep fragmenta-
tion with repeated arousals occurs in both COPD [7] and OSA
[8] patients. These arousals are usually associated with acute
surges in heart rate and blood pressure so, contribute to the
adverse cardiovascular consequences [8].
The measurement of circulating cardiovascular risk mark-
ers enables more accurate prediction of cardiovascular disor-
ders [9]. Lp-PLA2 is a novel biomarker of vascular-speciﬁc
inﬂammation which provides information about atheroscle-
rotic plaques [10,11]. It is a macrophage-derived enzyme that
may play an important role in the link between inﬂammation,
oxidation and atherosclerosis [12]. It has been strongly associ-
ated with several cardiovascular risk markers and events [13].
Little is known about this issue especially in COPD and
OSA patients. Therefore, the aim of this work was to study
the association between circulating LP-PLA2 and arousals in
patients with COPD, OSA and overlap syndrome.
Subjects and methods
This study was performed in Minouﬁya University Hospital
including 45 adult patients with suspected sleep disorders
compared with 15 healthy volunteers as controls. All partici-
pants underwent diagnostic polysomnography (PSG) in the
Sleep Disorder Unit between March 2012 and January 2013.
Before the beginning of the study, Ethics approval was ob-
tained from the Minouﬁya Hospital’s Review Board and a
written informed consent was obtained from all participants
prior to subject characterization and sample collections.
The patients were classiﬁed into three matched groups (each
of 15 patients) according to their polysomnographic and spiro-
metric data; newly diagnosed OSA group, COPD group, and
overlap syndrome group. The normal controls were healthy,
life-long nonsmoking volunteers who had no history of lung
or cardiovascular diseases. OSA was deﬁned as an apnea-
hypopnea index (AHI) of P5 obstructive events per hour ofsleep [14]. Chronic airﬂow obstruction was deﬁned spirometri-
cally as a post-bronchodilator forced expiratory volume in the
ﬁrst second (FEV1)/forced vital capacity (FVC) <70% and an
FEV1 6 80% of predicted values [15]. The exclusion criteria
were hypertension, coronary artery disease, heart failure, a his-
tory of stroke, diabetes mellitus, chronic pulmonary disease
(other than COPD), chronic renal disease, pharmacologically
treated depression and tobacco use within the past 10 years.
In addition, nightshift workers and patients receiving medica-
tions or nutritional supplements were ineligible for the study.
Polysomnography
A full-night polysomnography (PSG) was performed by using
Embla S4000 Medcare, Iceland. The system has Somnologica
studio 3.3.2 software, electrodes and cables to record the elec-
troencephalogram, electrooculogram, electromyogram of the
chin and bilateral tibialis anterior muscles, electrocardiogram.
Airﬂow was measured using both a nasal cannula and nasal
thermistor, oxygen saturation was measured using a pulse
oximeter, and chest and abdominal respiratory movements
were monitored by respiratory inductive polysthmography
belts. Snoring was recorded using microphones attached to
the neck. Body position wasmonitored using body position sen-
sor. Before electrode application, the patient completed a sleep
questionnaire including the Epworth sleepiness scale (ESS). All
studies were analyzed using the criteria of Rechtschaffen and
Kales, [16] and in close concordance with scoring updates given
by the American Academy of Sleep Medicine [17].
Blood sampling
In the morning, 5 ml of venous blood samples were withdrawn
at 9:00 A.M. from subjects after overnight fasting. The venous
blood was transferred slowly into a plain tube, allowed to clot,
and then centrifuged for ten minutes. The clear supernatant
was separated in several aliquots, kept frozen at 20 C, till
analysis of lipid proﬁle and Lp-PLA2 level.
Measurements of pulmonary functions
Then, all participants underwent spirometric testing on the sec-
ond day of the sleep study in Pulmonary Function Test Unit in
Minouﬁya University Hospital. Pulmonary functions were
measured with a turbine spirometer ‘‘Quark PFT3, COSMED,
Italy’’, based on a forced vital capacity maneuver, in which the
participants were requested to exhale the maximal volume of
air during a forced expiratory maneuver starting from a posi-
tion of full inspiration and ending at complete expiration [18].
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Quantitative determination of total cholesterol, HDLc and
triacylglycerides (TG) using colorimeteric enzymatic method
[19]. LDLc was calculated as TG< 400 mg/dl the formula
of Friedewald et al. [20]. Enzyme linked immunosorbant assay
(ELISA) was used for the quantitative determination of Lipo-
protein-associated phospholipase A2 by a dual monoclonal
antibody immunoassay [21].
Statistical methods
Data were analyzed by the SPSS version 11.0 statistical pack-
age. The quantitative data were expressed as mean and stan-
dard deviation (Mean ± SD). The qualitative data wereTable 1 Demographic, polysomnographic and spirometric data of
Control OSA
Male (n.,%) 9, 60% 9,60%
Age 48.73 ± 8.04 50.53 ± 1
P1 >0.05
P2
P3
BMI (Kg/m2) 24.27 ± 2.65 47.20 ± 1
P1 <0.001
P2
P3
ESS 4.53 ± 1.92 15.27 ± 4
P1 <0.001
P2
P3
Arousal index 5.07 ± 2.68 55.27 ± 1
P1 <0.001
P2
P3
Sleep eﬃciency % 82.47 ± 5.12 53.80 ± 9
P1 <0.001
P2
P3
AHI 2.60 ± 1.59 51.33 ± 1
P1 <0.001
P2
P3
O2 DI 4.20 ± 1.52 48.27 ± 9
P1 <0.001
P2
P3
FVC % 86.87 ± 3.37 69.80 ± 4
P1 <0.001
P2
P3
FEV1/FVC 87.87 ± 4.73 87.60 ± 4
P1 >0.05
P2
P3
BMI, body mass index; ESS, Epworth Sleepiness Scale; AHI, apnea-hyp
Except for the gender, results are expressed as mean ± SD (n= 15).
P1: signiﬁcant when compared to control group, P2: signiﬁcant when compexpressed as number and percentage. The one way ANOVA
F-test was used for the normally distributed variables. Correla-
tion between variables was calculated by Spearman and Pear-
son correlation coefﬁcient. All these tests were used as tests of
signiﬁcance at p< 0.05 level.Results
Table 1 shows the demographic, polysomnographic and spiro-
metric data in all studied groups. There were signiﬁcantly high-
er apnea–hypopnea, arousal, and desaturation indices and a
signiﬁcantly lower sleep efﬁciency in all patient groups com-
pared to their corresponding values in the control group.
Fig. 1 shows signiﬁcantly higher levels of fasting serum cho-
lesterol, triglycerides and LDL in all patient groups comparedall studied groups.
COPD Overlap Syndrome
10,66.7% 10,66.7%
4.45 52.53 ± 11.89 58.93 ± 7.40
>0.05 <0.001
>0.05 >0.05
>0.05
0.05 40.67 ± 7.43 44.00 ± 7.91
<0.001 <0.001
>0.05 >0.05
>0.05
.18 13.33 ± 3.63 16.47 ± 3.04
<0.001 <0.001
>0.05 >0.05
<0.05
4.68 39.80 ± 9.87 70.53 ± 15.51
<0.001 <0.001
<0.01 <0.05
<0.001
.79 65.40 ± 12.56 8.31 34.27±
<0.001 <0.001
<0.01 <0.001
<0.001
0.00 5.73 ± 1.83 53.27 ± 27.25
<0.001 <0.001
<0.001 >0.05
<0.001
.07 19.87 ± 5.29 50.80 ± 10.08
<0.001 <0.001
<0.001 >0.05
<0.001
.76 60.87 ± 8.80 52.40 ± 7.86
<0.001 <0.001
<0.01 <0.001
<0.05
.76 61.60 ± 6.63 59.80 ± 5.73
<0.001 <0.001
<0.001 <0.001
>0.05
opnea index; O2 DI, O2 desaturation index.
ared to OSA group. P3: signiﬁcant when compared to COPD group.
Figure 1 Serum lipid proﬁle in all studied groups.
Table 3 Stepwise linear regression analysis to determine the
independent predictors of total arousal index in OSA, COPD
and overlap syndrome.
Arousal index
OSA COPD Overlap syndrome
LP-PLA2 B 0.460 0.740 0.873
P 0.000** 0.000** 0.000**
Cholesterol B 0.68 0.009 0.131
P 0.58 0.94 0.22
Triglycerides B 0.053 0.104 0.39
P 0.54 0.45 0.64
LDL B 0.175 0.229 0.64
P 0.17 0.16 0.66
HDL B 0.229 0.290 0.055
P 0.60 0.5 0.78
** highly signiﬁcant correlation (p< 001)
408 E.A.E. Badr et al.to their corresponding values in the control group. It also
shows a signiﬁcant decrease in fasting serum HDL level
compared to its corresponding value in the control group.
Fig. 2 shows the LP-PLA2 levels in all studied groups.
There was a signiﬁcant elevation in the enzyme level in allFigure 2 Lipoprotein-associated phospholipase A2 levels in all
studied groups.
Table 2 Correlation analysis between total arousal index and
laboratory parameters in patients with OSA, COPD and
overlap syndrome.
Arousal index
OSA COPD Overlap syndrome
LP-PLA2 r 0.971 0.95 0.98
p 0.000** 0.000** 0.000**
Cholesterol r 0.27 0.177 0.87
p 0.32 0.52 0.000**
Triglycerides r 0.43 0.38 0.73
p 0.101 0.15 0.002*
LDLc r 0.39 0.80 0.73
p 0.14 0.77 0.002*
HDLc r 0.08 0.34 0.30
p 0.76 0.206 0.27
* highly signiﬁcant correlation (p< 001)
** highly signiﬁcant correlation (p< 001)patient groups compared with their corresponding value in
the control group. The enzyme level was signiﬁcantly higher
in overlap syndrome compared to its corresponding values in
OSA and COPD groups.
Table 2 shows signiﬁcant positive correlations between to-
tal arousal index and the level of LP-PLA2 in all patient
groups. Also, cholesterol, triglycerides and LDL levels show
signiﬁcant positive correlation with total arousal index in over-
lap syndrome.
Table 3 shows the stepwise linear regression analysis test. It
shows that the LP-PLA2 was an independent predictor of
arousal index in all patient groups.
Discussion
The association of cardiovascular events with Lp-PLA2 is
being studied continuously today. In addition to repetitive
arousals which are common occurrence in OSA and in COPD
patients and are also linked to high cardiovascular complica-
tions. However, it seems likely that the overlap syndrome is
associated with greater cardiovascular complications than each
disorder alone, although detailed studies are required to prove
this hypothesis. Therefore, this work aimed at studying the
relation between circulating LP-PLA2 and arousals in patients
with OSA, COPD and overlap syndrome.
This study showed that the sleep quality is poor in the three
patient groups and that patients with overlap syndrome have a
signiﬁcantly lower sleep efﬁciency and higher arousal index
than OSA and COPD groups (Table 1). This matches the re-
sults of Breslin E et al. [22] who found that in patients with se-
vere COPD there was a sleep fragmentation with reduced sleep
efﬁciency, and disrupted sleep architecture. This sleep disorga-
nization with recurrent arousals may be related to nocturnal
cough and dyspnea, alterations in gas exchange, medications
or general debility associated with COPD [23,24]. However,
Sanders et al. [25] had found in 1132 patients with mild COPD
that in those patients with COPD alone, sleep can be mini-
mally disrupted and small differences regarding the sleep qual-
ity were found between patients with OSA alone and those
with overlap syndrome, therefore they conclude that sleep
quality in patients with overlap syndrome is mostly inﬂuenced
by the presence of OSA. Arousal is a critical defense mecha-
nism that activates upper airway dilator muscles and prevents
asphyxiation in OSA [26].
Lp-PLA2 levels as a predictor of cardiovascular risks 409Frequent arousal and sleep disturbance in OSA and in
COPD patients are usually associated with acute increase in
blood pressure and heart rate [3]. Furthermore, recurrent
arousals, together with abnormalities in arterial blood gases
and large swings in the intra-thoracic pressures initiate activa-
tion of neuro-hormones, hyper-coagulopathy, oxidative stress,
release of inﬂammatory mediators and eventually contribute to
cardiovascular complications [27].
In this study, there was a signiﬁcant elevation in fasting ser-
um cholesterol, triglycerides, LDL and LP-PLA2 (Fig. 1) that
was observed in all patient groups. This pattern of dyslipide-
mia may predispose to atherosclerosis and endothelial
dysfunction [1]. Another mechanism is involved in the COPD,
that it increases elastolytic activity which promotes connective
tissue degradation resulting in arterial stiffness and atheroscle-
rosis [28].
This study showed a positive correlation between LP-PLA2
levels and arousal index (Table 2). Moreover, LP-PLA2 was an
independent predictor of arousal index in all patient groups
(Table 3). This is in agreement with Bekci et al. [29] who stud-
ied the association among arousal, circulating Lp-PLA2 in 50
male patients with OSA. They found that higher arousal index
was associated with increased LP-PLA2 level and the elevated
levels of circulating LP-PLA2 may explain prone to sudden
death due stroke and acute myocardial infarction in patients
with OSA and increased arousal index.
This enzyme is involved in lipid metabolism generating pro-
inﬂammatory and proapoptotic lipid mediators [30,31]. These
proinﬂammatory lipids play an important role in the develop-
ment of atherosclerotic necrotic cores, the substrate for acute
unstable coronary disease [32]. So, increased level of Lp-
PLA2 is associated with an increased risk of cardiovascular
complications.
It can be concluded that the overlap syndrome is associated
with frequent arousals and sleep fragmentation and has higher
level of Lp-PLA2 than COPD or OSA alone, the present study
demonstrated that a high arousal index was associated with
increased LP-PLA2 level which may have signiﬁcant
cardiovascular implications in these patients. Lp-PLA2 also,
may be used as an independent predictor of cardiovascular
disorders in OSA, COPD and overlap syndrome.
Study limitations: this study should be interpreted in the
context of the small number of patients in each group, no data
about the cardiac assessment of the studied patients. No data
about the duration of disease and medications prior to
enrollment.
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